Table 1 Baseline characteristics of patients.
From: The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases
All (n = 220) | R group (n = 82) | E group (n = 138) | P value | |
|---|---|---|---|---|
Age (years) | 71.0 (66.0–76.0) | 70.0 (63.8–74.3) | 72.0 (66.8–78.0) | 0.080 |
Male, sex | 148 (67.3) | 62 (75.6) | 86 (62.3) | 0.053 |
Weight (kg) | 59.0 (49.8–65.5) | 62.0 (52.5–66.6) | 55.5 (48.0–64.2) | 0.010 |
Ever-Smokers | 141 (64.1) | 59 (72.0) | 82 (59.4) | 0.081 |
AF | 84 (38.2) | 40 (48.8) | 44 (31.9) | 0.015 |
VTE | 139 (63.2) | 41 (50.0) | 98 (71.0) | 0.002 |
DVT | 126 (57.3) | 33 (40.2) | 93 (67.4) | < 0.001 |
PTE | 44 (20.0) | 18 (22.0) | 26 (18.8) | 0.604 |
Pulmonary disease | ||||
Lung cancer | 76 (34.5) | 29 (35.4) | 47 (34.1) | 0.884 |
COPD | 69 (31.4) | 30 (36.6) | 39 (28.3) | 0.230 |
ILD | 68 (30.9) | 26 (31.7) | 42 (30.4) | 0.881 |
Bronchial asthma | 47 (5.8) | 17 (20.7) | 30 (21.7) | 1.000 |
Post thoracic surgery | 45 (20.5) | 22 (26.8) | 23 (16.7) | 0.084 |
Bronchiectasis | 11 (5.0) | 3 (3.7) | 8 (5.8) | 0.750 |
NTM | 7 (3.2) | 2 (2.4) | 5 (3.6) | 1.000 |
Others | 23 (10.5) | 9 (11.1) | 14 (10.1) | 1.000 |
Antiplatelet agents | 37 (16.8) | 11 (13.4) | 26 (18.8) | 0.354 |
Interacting drugs with FXa inhibitors | 85 (38.6) | 26 (31.7) | 59 (42.8) | 0.117 |
NSAIDs | 40 (11.8) | 10 (12.2) | 30 (21.7) | 0.103 |
SSRI | 26 (11.5) | 13 (15.9) | 13 (9.4) | 0.195 |
Macrolide antibiotics | 17 (7.7) | 2 (2.4) | 15 (10.9) | 0.027 |
Herbesser | 7 (3.2) | 3 (16.7) | 3 (8.8) | 0.406 |
Laboratory findings | ||||
CRP (mg/dL) | 0.9 (0.2–4.0) | 0.8 (0.2–4.0) | 0.9 (0.2–4.3) | 0.787 |
eGFR (mL/min/1.73m2) | 60.2 (42.3–81.5) | 71.0 (62.0–86.0) | 64.0 (41.4–73.3) | 0.176 |
